Decreased Associated Risk of Gout in Diabetes Patients with Uric Acid Urolithiasis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2019 Sep 28

PMID 31557790

Citations 5

Authors

Chan Jung Liu

Jin Shang Wu

Ho Shang Huang

Affiliations

Soon will be listed here.

Abstract

Uric acid urolithiasis constitutes approximately 7-10% of all urinary stones. Previous studies have revealed that patients with gout do not equally have uric acid stones. Instead, the risk of gout in patients with uric acid stones remains controversial. This study aimed to investigate whether there is different associated risk of gout for diabetes mellitus (DM) and non-diabetes patients with uric acid urolithiasis. Therefore, we examined all baseline chemistries to determine any risk factors or protective factors related to developing gout in patients with uric acid stones. Ninety-nine patients from a single medical center, who had a uric acid component in their stone specimen were enrolled and their medical records were reviewed retrospectively between January 2010 and December 2016. All patients were divided into gout and non-gout groups. Gout was confirmed in 24 patients in this study (24.2%). The proportion of DM was significantly higher in the non-gout group (34.7%) than in the gout group (4.3%, < 0.05). Renal function was decreased and serum triglyceride was higher in patients with gout. Uric acid urolithiasis patients with DM had a lower risk for gout (adjusted odds ratio: 0.08; 95% confidence interval (CI) = 0.01-0.61, = 0.015). In 89 patients with predominant uric acid stones (>50% uric acid composition), the risk for gout was still lower in patients with diabetes than non-diabetes (adjusted odds ratio: 0.08; 95% confidence interval (CI) = 0.01-0.61, = 0.015). These findings suggest that decreased risk of gout is found in uric acid urolithiasis patients with diabetes. Our results imply that patients with uric acid stones should have complete diabetes evaluation before the administration of uric acid controlling medication.

Citing Articles

The Effects of Astaxanthin on Metabolic Syndrome: A Comprehensive Review.

Gao C, Gong N, Chen F, Hu S, Zhou Q, Gao X Mar Drugs. 2025; 23(1).

PMID: 39852511 PMC: 11766962. DOI: 10.3390/md23010009.

Risks of Carotid Artery Stenosis and Atherosclerotic Cardiovascular Disease in Patients with Calcium Kidney Stone: Assessment of Systemic Inflammatory Biomarkers.

Liu C, Jan H, Huang H J Pers Med. 2022; 12(10).

PMID: 36294835 PMC: 9604970. DOI: 10.3390/jpm12101697.

Prediction of the composition of urinary stones using deep learning.

Kim U, Kwon H, Yang W, Lee W, Choi C, Kim J Investig Clin Urol. 2022; 63(4):441-447.

PMID: 35670006 PMC: 9262483. DOI: 10.4111/icu.20220062.

Atorvastatin Decreases Renal Calcium Oxalate Stone Deposits by Enhancing Renal Osteopontin Expression in Hyperoxaluric Stone-Forming Rats Fed a High-Fat Diet.

Liu C, Tsai Y, Huang H Int J Mol Sci. 2022; 23(6).

PMID: 35328466 PMC: 8954580. DOI: 10.3390/ijms23063048.

Medical evaluation and pharmacotherapeutical strategies in management of urolithiasis.

Ng D, Haleem M, Mamuchashvili A, Wang K, Pan J, Cheng Y Ther Adv Urol. 2021; 13:1756287221993300.

PMID: 33708261 PMC: 7907714. DOI: 10.1177/1756287221993300.

References

Kenny J, Goldfarb D . Update on the pathophysiology and management of uric acid renal stones. Curr Rheumatol Rep. 2010; 12(2):125-9. DOI: 10.1007/s11926-010-0089-y. View

Reichard C, Gill B, Sarkissian C, De S, Monga M . 100% uric acid stone formers: what makes them different?. Urology. 2015; 85(2):296-8. DOI: 10.1016/j.urology.2014.10.029. View

Maalouf N, Cameron M, Moe O, Sakhaee K . Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens. 2004; 13(2):181-9. DOI: 10.1097/00041552-200403000-00006. View

Torricelli F, De S, Gebreselassie S, Li I, Sarkissian C, Monga M . Dyslipidemia and kidney stone risk. J Urol. 2013; 191(3):667-72. DOI: 10.1016/j.juro.2013.09.022. View

Wiederkehr M, Moe O . Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder. Clin Rev Bone Miner Metab. 2014; 9(3-4):207-217. PMC: 4100778. DOI: 10.1007/s12018-011-9106-6. View

Wallace S, Robinson H, MASI A, Decker J, McCarty D, Yu T . Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977; 20(3):895-900. DOI: 10.1002/art.1780200320. View

Pak C, Poindexter J, Peterson R, Koska J, Sakhaee K . Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. Urology. 2002; 60(5):789-94. DOI: 10.1016/s0090-4295(02)01908-8. View

Pak C, Moe O, Sakhaee K, Peterson R, Poindexter J . Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. J Urol. 2005; 173(5):1606-9. DOI: 10.1097/01.ju.0000154611.64362.66. View

So A, Martinon F . Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017; 13(11):639-647. DOI: 10.1038/nrrheum.2017.155. View

10.

Alberti K, Zimmet P, Shaw J . The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-8. View

11.

Choi H, Atkinson K, Karlson E, Willett W, Curhan G . Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004; 350(11):1093-103. DOI: 10.1056/NEJMoa035700. View

12.

Kramer H, Choi H, Atkinson K, Stampfer M, Curhan G . The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int. 2003; 64(3):1022-6. DOI: 10.1046/j.1523-1755.2003.t01-2-00171.x. View

13.

Maalouf N, Cameron M, Moe O, Sakhaee K . Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010; 5(7):1277-81. PMC: 2893060. DOI: 10.2215/CJN.08331109. View

14.

Leiba A, Vinker S, Dinour D, Holtzman E, Shani M . Uric acid levels within the normal range predict increased risk of hypertension: a cohort study. J Am Soc Hypertens. 2015; 9(8):600-9. DOI: 10.1016/j.jash.2015.05.010. View

15.

Maalouf N . Metabolic syndrome and the genesis of uric acid stones. J Ren Nutr. 2011; 21(1):128-31. PMC: 3053068. DOI: 10.1053/j.jrn.2010.10.015. View

16.

Shimizu T, Hori H . The prevalence of nephrolithiasis in patients with primary gout: a cross-sectional study using helical computed tomography. J Rheumatol. 2009; 36(9):1958-62. DOI: 10.3899/jrheum.081128. View

17.

Kuo K, Chang Y, Wu I, Lu F, Yang Y, Wu J . Differences in the association between glycemia and uric acid levels in diabetic and non-diabetic populations. J Diabetes Complications. 2019; 33(8):511-515. DOI: 10.1016/j.jdiacomp.2019.05.004. View

18.

Torricelli F, De S, Gebreselassie S, Li I, Sarkissian C, Monga M . Type-2 diabetes and kidney stones: impact of diabetes medications and glycemic control. Urology. 2014; 84(3):544-8. DOI: 10.1016/j.urology.2014.02.074. View

19.

Moe O, Richie Xu L . Hyperuricosuric calcium urolithiasis. J Nephrol. 2018; 31(2):189-196. DOI: 10.1007/s40620-018-0469-3. View

20.

Kang H, Lee S, Kim W, Kim Y, Yun S, Lee S . Hypertriglyceridemia and low high-density lipoprotein cholesterolemia are associated with increased hazard for urolithiasis. J Endourol. 2014; 28(8):1001-5. DOI: 10.1089/end.2014.0135. View